Explore
Validate
LearnRA0475
antibody from Oursmab
Targeting: MAPT
DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- RA0475 - Provider product page
- Provider
- Oursmab
- Product name
- Bepranemab (Biosimilar Reference Antibody) (MAPT)
- Antibody type
- Monoclonal
- Description
- Bepranemab is an investigational, humanized monoclonal antibody designed to target Tau protein. It specifically binds to the central region of the Tau protein, aiming to prevent its pathological cell-to-cell propagation and aggregation in the brain. By targeting this region, it is intended to inhibit the spread of Tau pathology, which is a key driver of neurodegeneration in diseases like Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). It is currently in clinical development (Phase II) for the treatment of these Tauopathies.
- Reactivity
- Human
- Isotype
- IgG
- Vial size
- 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
- Concentration
- Bottled at the concentration indicated on the vial.
- Storage
- Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
No comments: Submit comment
No validations: Submit validation data